IMPORTANCE Allogeneic blood or marrow transplantation (BMT) is a curative option for malignant and nonmalignant diseases of childhood. However, little is known about trends in cause-specific late mortality in this population during the past 3 decades.
A llogeneic blood or marrow transplantation (BMT) is now a curative option for many malignant and nonmalignant diseases of childhood. [1] [2] [3] Nonetheless, the high intensity of therapeutic exposures at a young age increases the risk of organ compromise and may lead to late mortality. Earlier studies of cohorts of adults who have undergone allogeneic BMT, as well as studies in mixed cohorts of both children and adults, have shown an increased risk of late mortality, primarily due to recurrent disease, subsequent malignant neoplasm, chronic graft-vs-host disease (cGvHD), infections, and cardiovascular and pulmonary disease. 4 -10 A few studies have examined late mortality after allogeneic BMT performed solely in childhood; these studies are limited by their relatively small sample sizes. 11-15 Furthermore, it is not clear whether the mortality rates have changed during the past 3 decades in response to changes in transplant practice. We address these knowledge gaps by examining all-cause mortality, relapserelated mortality (RRM), and non-RRM in a large cohort of individuals who have lived 2 years or more after allogeneic BMT performed in childhood between 1974 and 2010.
Methods
The Blood or Marrow Transplant Survivor Study-2 is a collaborative effort between City of Hope, the University of Minnesota, and the University of Alabama at Birmingham examining the long-term outcome of individuals who have lived 2 years or more after BMT. To be included in this analysis, patients had to have received allogeneic BMT at City of Hope or the University of Minnesota between January 1, 1974, and December 31, 2010, at age 21 years or younger and lived for at least 2 years after transplantation. Patients who received a second BMT were excluded. The Human Subjects Committee at City of Hope and the University of Minnesota approved the Blood or Marrow Transplant Survivor Study-2 protocol. Written informed consent was obtained in accordance with the Declaration of Helsinki. 16 Data on primary diagnosis, therapeutic agents used for preparative regimens, type of donor stem cells (related or unrelated donor), stem cell source, disease status at transplantation, and agents used for cGvHD prophylaxis, as well as demographic characteristics, were obtained on all eligible cases from the institutional transplant databases. National Death Index Plus 17 and/or medical records provided data regarding the date and cause of death through December 31, 2015. Additional data from medical records and Accurint databases 18 were used to extend the vital status information through December 31, 2016. All patients were assigned a primary and, if present, a secondary cause of death independently by 2 separate investigators (A.S.H. and J.W.). In the event of discrepant assignments, a third investigator (S.B.) provided adjudication. In the analyses of RRM and non-RRM, all patients with primary disease as a primary or secondary cause of death were assigned a relapse-related cause of death.
Statistical Analysis
Kaplan-Meier techniques were used to describe overall survival, conditional on living 2 years or more and 20 years or more after allogeneic BMT, as well as all-cause late mortality for patients receiving allogeneic BMT in 3 time periods: prior to 1990, 1990-1999, and 2000-2010 . The standardized mortality ratio (SMR), a ratio of observed to expected number of deaths, was used to compare the mortality experienced by this cohort with the age-specific (5-year interval), sex-specific, and calendarspecific (5-year interval) mortality of the US general population. Person-years at risk were computed from the date 2 years after allogeneic BMT to either the date of death or the date of censoring (December 31, 2016), whichever occurred first. The expected number of deaths was calculated by multiplying the number of person-years in each defined stratum by the corresponding US mortality rates obtained from the Centers for Disease Control and Prevention. 19 The Poisson regression method described by Vandenbroucke 20 was used to calculate 95% CIs of the SMR. Absolute excess risk (AER) was defined as the difference between the observed and expected number of deaths per 1000 person-years of follow-up. Cumulative incidence rates for RRM and non-RRM were calculated using competing risk methods. Cox proportional hazards regression analysis was used for identifying factors associated with all-cause mortality. The assumption of proportionality was tested, and all variables met the assumption (P > .05). A proportional subdistribution hazards (Fine-Gray) model for competing risks was used for identifying potential risk factors for RRM and non-RRM. The evaluated risk factors included age at allogeneic BMT, sex, race/ethnicity, primary disease, donor type, stem cell source, conditioning regimen, disease status at transplantation (standard or high risk of relapse at allogeneic BMT), and transplant time period. Mediation analysis was performed by adding each risk factor, one at time, to transplant time period, examining its association with the difference in late mortality across the transplant time periods; thus, using patients who underwent transplantation before 1990 as the referent group, we examined the hazard of late mortality for patients who underwent transplantation between 1990 and 1999 and those who underwent transplantation between 2000 and 2010 without adjustment for clinical or demographic factors. We then included each of these factors in separate models to examine if the hazard ratios (HRs) changed. Patients who underwent allogeneic BMT in the first or second complete remission after acute leukemia or lymphoma or in the first chronic phase of chronic myelogenous leukemia, as well as all patients with severe aplastic anemia, were considered at standard risk for relapse at transplantation; all other patients, excluding those already mentioned, were considered at high risk. Two-sided tests with P < .05 were considered statistically significant. All analyses were performed with SAS software, version 9.4 (SAS Institute Inc).
Results

Patient Characteristics
The demographic and clinical characteristics of the cohort are shown in Table 1 Figure 1A , revealing no difference in survival by sex. Conditional on living 20 years after BMT, the subsequent 5-year overall survival was 94.2% for the entire cohort (eTable 1 in the Supplement). Table 2 summarizes the SMRs in this population using agespecific, sex-specific, and calendar-specific rates from the general US population. Overall, the cohort was at a 14.4-fold increased risk for premature death (95% CI, 12.8-16.1) compared with the general population (292 deaths observed; 20.3 deaths expected). Relative mortality was elevated across all ages at transplantation but was highest for patients who underwent transplantation at age 5 to 9 years (SMR, 22.8; 95% CI, 17.9-28.4). The SMRs were higher for female patients (23.6; 95% CI, 19.6-28.0) compared with male patients (11.2; 95% CI, 9.6-13.0; P < .001). The SMRs were highest for patients who underwent transplantation in the most recent time period (20.8; 95% CI, 16.4-25.9), likely owing to the low mortality rates among the corresponding children in the general population. The SMRs were higher among those who underwent transplantation for disease at high risk of relapse (23.3; 95% CI, 21.2-25.6) and those who had received an unrelated donor BMT (19.9; 95% CI, 16.0-24.3). High relative mortality was observed across all primary diagnoses, with SMRs ranging from 4.6 (SAA) to 28.2 (inborn errors of metabolism).
Relative Mortality
Relative mortality was highest in the 2-to 5-year period after BMT (SMR, 522.0; 95% CI, 439.9-613.6) but decreased rapidly thereafter. However, it remained significantly elevated even at 25 years or more after transplantation (SMR, 2.9; 95% CI, 2.0-4.1).
The AER for death from any cause for the whole cohort was 12.0 per 1000 person-years (95% CI, 10.5-13.5). The AERs did not vary significantly by sex, age at BMT, type of donor, or transplant time period (Table 2 ). The AERs were higher for those with disease that was at high risk of relapse (15.1; 95% CI, 12.6-17.6) than those with disease at standard risk of relapse (9.9; 95% CI, 8.1-11.7). The AER was highest in the period between 2 and 5 years after BMT (310.8; 95% CI, 259.0-362.6) and decreased progressively thereafter, but it was significantly elevated among those who had lived 25 years or more after BMT (2.6; 95% CI, 1.2-3.9).
Specific Causes of Death
A cause of death was available for 244 of the 295 deceased patients (82.7%), in part because we had National Death Index Plus data through 2015 and vital status data through 2016. . The cumulative incidence of cause-specific mortality is shown in eFigure 1 in the Supplement. The 10-year cumulative incidence of the most prevalent causes of death was as follows: 4.4% (95% CI, 3.4%-5.6%) for infection; 2.5% (95% CI, 1.7%-3.4%) for cGvHD; and 1.6% (95% CI, 1.0%-2.4%) for subsequent malignant neoplasm (eTable 2 in the Supplement). A total of 49 of the 60 deaths due to primary disease (81.7%) occurred within the first 2 to 9 years after transplantation. The cumulative incidence of non-RRM was 13.2% at 20 years after BMT, while that of RRM was only 4.5% ( Figure 1B ). A, Cumulative all-cause mortality by sex at 10 years (female patients, 14.3%; male patients, 12.8%; P = .78). B, Cumulative non-relapse-related mortality (non-RRM) at 20 years (13.2%) and relapse-related mortality (RRM) at 20 years (4.5%).
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Late conditioning regimen (HR, 0.62; 95% CI, 0.41-0.95) compared with those who received total body irradiation and cyclophosphamide.
Compared with patients who underwent transplantation for acute lymphoblastic leukemia, the hazard of RRM was lower among patients who underwent transplantation for acute 
Late Mortality by Treatment Time Period
The demographic and clinical characteristics of the present cohort by treatment time period are detailed in eTable 3 in the Supplement, and noteworthy differences are illustrated in eFigure 2 in the Supplement. There was a decrease in the proportion of non-Hispanic white individuals undergoing BMT, with a concomitant increase in the proportion of African American and Hispanic individuals. There was an increase in the number of unrelated donor BMTs and an increase in the number of peripheral blood stem cell transplants and cord blood stem cell transplants. Use of total body irradiation decreased. The number of patients who underwent transplantation with high-risk disease increased. The all-cause, 10-year cumulative mortality rate decreased during the 3 time periods (18.9% prior to 1990, 12.9% in 1990-1999, and 11.0% in 2000-2010; P = .002) (Figure 2) . Adjusting for demographic and clinical variables (including all the variables that had changed significantly during the 3 time periods), the HR of all-cause death decreased with time (referent group, prior to 1990; 1990-1999: HR, 0.64; 95% CI; 0.47-0.89; P = .007; 2000-2010: HR, 0.49; 95% CI, 0.31-0.76; P = .002; P < .001 for trend) ( Table 3 ). As shown in Table 3 , the adjusted hazard of non-RRM decreased significantly during the treatment time periods; however, the decrease in RRM did not approach statistical significance. Mediation analysis, including clinical transplant practice variables as well as demographic factors, did not explain the decrease in late mortality over time (eTable 4 in the Supplement).
Discussion
This study on late mortality among individuals who lived 2 years or more after allogeneic BMT performed in childhood shows that these patients remain at an elevated risk of premature death compared with the general population even 25 years after transplantation. Although the risk of RRM plateaus with time, non-RRM continues to increase and remains the major cause of excess late death in this population. Most important, there has been a significant decrease in all-cause mortality experienced by children undergoing allogeneic BMT during the past 3 decades.
The present study demonstrates that patients who live 2 or more years after allogeneic BMT performed at age 21 years or younger have an overall survival rate that approaches 80% at 20 years after transplantation. This study also demonstrates that this cohort is at a 14-fold increased risk of premature death compared with the general population. The mortality rate continues to be significantly higher among those who live 25 or more years after transplantation. An Australian cohort of individuals who lived 2 years or more after pediatric allogeneic BMT had an SMR of 35.9 compared with the general population. 13 However, unlike our study, the Australian cohort included only malignant disorders. Similar to the previously published Australian study, 13 we found that the SMRs were highest among those who underwent transplantation at a young age, likely owing to the negligible death rates at this age in the general population. However, we found that the AER was lowest among those who underwent transplantation at 4 years or younger and was relatively similar across the other age groups. In the present study, high relative mortality was observed across all primary diagnoses, with the highest rates among individuals with a primary diagnosis of inborn errors of metabolism, Fanconi anemia, and acute lymphoblastic leukemia. The SMR among individuals who underwent transplantation for SAA was considerably lower. Among individuals who lived 2 years or more after allogeneic BMT for inborn errors of metabolism, a previous report found a 7-year overall survival rate of 90%, which is comparable to our study. 21 The lower relative mortality rates among individuals who lived 2 years or more after allogeneic BMT for SAA are in concordance with previously published results. 4, 9 The cumulative all-cause mortality and the AER did not differ significantly between the sexes, although a higher SMR was found among female patients rather than male patients. However, the latter finding can likely be explained by higher mortality rates among younger male patients in the general population. We show for the first time, to our knowledge, that while the risk of RRM plateaus with time, non-RRM continues to increase and remains the major cause of late death in this population. In our study, only 25% of the late deaths were caused by the primary disease, while 65% died of relapse in the study by Schechter et al. 12 Again, the latter study was smaller and restricted to malignant diseases. The proportion of late deaths attributed to primary disease was also higher in the Australian report that included only malignant diseases (73% [32 deaths]). 13 However, the proportions of late deaths due to primary disease in larger studies, although based on mixed cohorts of adults and children treated with allogeneic BMT for malignant diseases, are more comparable to ours. In the present study, we found that there has been a significant decrease in all-cause late mortality among children undergoing allogeneic BMT during the past 3 decades. Although there were significant changes in transplant practice during these 3 time periods, a mediation analysis including each of these transplant practices in the model failed to explain the decrease in mortality, suggesting that perhaps unmeasured variables (such as supportive care strategies, management of cGvHD, or improved patient selection for transplantation) could explain the decrease in late mortality.
In accordance with the existing literature on causespecific late mortality after allogeneic BMT, 4,5,7,10 primary disease, infection, subsequent malignant neoplasm, and cGvHD were the most common causes of death in this study. Chronic graft-vs-host disease and infection led to death primarily in the earlier part of follow-up, with 79% (cGvHD) and 78% (infection) occurring within the first 2 to 9 years after transplant. These findings underscore the need for close follow-up with regard to cGvHD and infections, in addition to relapse, during the first decade after transplantation. Subsequent malignant neoplasms accounted for 18% of the deaths observed in this study. Subsequent malignant neoplasms have also been reported as a significant cause of late mortality among adults undergoing allogeneic BMT. 4,5,7 Taken together, our results clearly show that long-term follow-up of individuals who lived 2 years or more after allogeneic BMT in childhood needs to include screening, preventive interventions, and counseling throughout life.
Limitations
Similar to the present study, most studies on cause-specific late mortality are based on causes of death registered on death certificates. Given the limitations of death certificates, some degree of misclassification is unavoidable. 5, 22, 23 Striving to partly overcome this bias, 3 of us (A.S.H., J.W., and S.B.) reviewed the causes of death recorded on the death certificates. Furthermore, information about the causes of death was lacking for 51 of the 295 deceased patients (17.3%). This study was also limited by the lack of data on pretransplant treatment.
Conclusions
These limitations notwithstanding, this study demonstrates that there has been a significant decrease in all-cause late mortality among children undergoing allogeneic BMT during the past 3 decades. Nevertheless, these individuals who lived 2 years or more after BMT remain at an elevated risk of late death even 25 years after BMT. Although the risk of RRM plateaus with time, non-RRM continues to increase and is the major cause of late death in this population. These findings emphasize the need for lifelong follow-up care after allogeneic BMT performed in childhood, focusing on the need for surveillance and early management of infections, cGvHD, and disease recurrence during the first decade after transplantation, as well as screening for early detection of subsequent malignant neoplasms and other complications throughout life. 
